1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Eisai, Purdue Join Up To Take Insomnia Drug Into Phase III

Eisai is teaming up with Purdue for the global development and commercialization of a dual orexin receptor, lemborexant, for insomnia and possibly other potential indications.

Eisai Inc., the US subsidiary of Japan’s Eisai Co. Ltd., and Purdue Pharma LP have joined forces to develop and commercialize Eisai’s lemborexant. The initial indication for the dual orexin receptor antagonist candidate is insomnia and the two companies will share the costs of the drug's global clinical studies in this area.

However, they may also seek to develop other

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.